Akorn, Inc. Receives FTC Clearance For Hi-Tech Pharmacal Acquisition

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Akorn’s acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). The unanimous vote in support of the transactions follows Akorn’s agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to consummate the acquisition, and intend to close by the end of this week.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC